tbuckley/cabot-search huggingface dataset:
Engineering of Uniform Epidermal Layers via Sacrificial Gelatin Bioink‐Assisted 3D Extrusion Bioprinting of Skin (Adv. Healthcare Mater. 27/2023)
Authors: Minjun Ahn, Won‐Woo Cho, Hanju Lee, Wonbin Park, Seok‐Hyeon Lee, Jae Woo Back, Qiqi Gao, Ge Gao, Dong‐Woo Cho, Byoung Soo Kim
Journal: Advanced Healthcare Materials (2023)
A Dual Heat Shock Protein Down‐Regulation Strategy Using PDA/Cu/ICG/R Controlled by NIR “Switch” Enhances Mild‐Photothermal Therapy Effect (Adv. Healthcare Mater. 27/2023)
Authors: Xin Ding, Tianyu Wang, Shiwei Bai, Mian Yang, Na Peng, Tao Qiu, Yi Liu
Journal: Advanced Healthcare Materials (2023)
Biomechanics, Energetics, and Structural Basis of Rupture of Fibrin Networks (Adv. Healthcare Mater. 27/2023)
Authors: Ranjini K. Ramanujam, Farkhad Maksudov, Rustem I. Litvinov, Chandrasekaran Nagaswami, John W. Weisel, Valerie Tutwiler, Valeri Barsegov
Journal: Advanced Healthcare Materials (2023)

Energetics of Ruptures Fibrin has a complex structural hierarchy that gives rise to the mechanical properties that are fundamental to preventing bleeding and thrombosis. In article 2300096, Valerie Tutwiler, Valeri Barsegov, and co-workers, study how changes in protein concentration impacts fibrin network structure and, transitively, its rupture resistance under applied tensile loads.
Development of a Novel DNA Aptamer Targeting Colorectal Cancer Cell‐Derived Small Extracellular Vesicles as a Potential Diagnostic and Therapeutic Agent (Adv. Healthcare Mater. 27/2023)
Authors: Byung Seok Cha, Young Jun Jang, Eun Sung Lee, Do Yeon Kim, Ji Su Woo, Jinseo Son, Seokjoon Kim, Jiye Shin, Jinjoo Han, Seokhwan Kim, Ki Soo Park
Journal: Advanced Healthcare Materials (2023)

Aptamers In article 2300854 by Ki Soo Park and co-workers, an aptamer is obtained through in vitro selection targeted at small extracellular vesicles (sEVs), which exhibits exceptional binding affinity and specificity toward colorectal cancer (CRC) and its specific interaction with CRC sEVs further hinders the potential metastatic pathways of CRC progression, ultimately enabling non-invasive diagnostics and therapeutics of CRC.
Adeno-associated viruses for gene therapy – clinical implications and liver-related complications, a guide for hepatologists
Authors: Marcus Maximilian Mücke, Sylvia Fong, Graham R. Foster, David Lillicrap, Wolfgang Miesbach, Stefan Zeuzem
Journal: Journal of Hepatology (2023)

Gene therapy has garnered increasing interest over recent decades. Several therapies employing gene transfer mechanisms have been developed, and, of these, adeno-associated virus (AAV) vectors have demonstrated viability for use with in vivo gene therapy. Several AAV-based therapeutics have received regulatory approval in the last few years including those for retinal disease, spinal muscular atrophy or aromatic L-amino acid decarboxylase deficiency. Lately, with the introduction of novel liver-directed AAV vector-based therapeutics for the treatment of haemophilia A and B, gene therapy has attracted significant attention in the hepatology community, with the liver increasingly recognised as a target for gene therapy. However, the introduction of foreign DNA into hepatocytes is associated with a risk of hepatic reactions, with raised ALT (alanine aminotransferase) and AST (aspartate aminotransferase) being - so far - the most commonly reported side effects. The complete mechanisms underlying the ALT flairs remain to be determined and the long-term risks associated with these new treatments is not yet known. The liver community is increasingly being asked to support liver-directed gene therapy to mitigate potential liver associated harm. In this review, we focus on AAV vector-based gene therapy, shedding light on this promising technique and its remarkable success in haemophilia, with a special focus on hepatic complications and their management in daily clinical practice.
A novel TNKS/USP25 inhibitor blocks the Wnt pathway to overcome multi-drug resistance in TNKS-overexpressing colorectal cancer
Authors: Hongrui Zhu, Yamin Gao, Liyun Liu, Mengyu Tao, Xiao Lin, Yijia Cheng, Yaoyao Shen, Haitao Xue, Li Guan, Huimin Zhao, Li Liu, Shuping Wang, Fan Yang, Yongjun Zhou, Hongze Liao, Fan Sun, Houwen Lin
Journal: Acta Pharmaceutica Sinica B (2023)

Modulating Tankyrases (TNKS), interactions with USP25 to promote TNKS degradation, rather than inhibiting their enzymatic activities, is emerging as an alternative/specific approach to inhibit the Wnt/
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. Was an accurate statistical analysis performed?
Authors: Luis E. Fernández-Garza
Journal: Journal of Hepatology (2023)

Non-selective beta-blockers (NSBBs) have been the cornerstone of the management of portal hypertension in cirrhosis for decades. The benefits of NSBBs are mainly observed in hemodynamic responders, defined as patients with a hepatic venous pressure gradient (HVPG) reduction of >20% or to an HVPG <12 mmHg.1 Previous studies have shown that 50% of patients will respond to traditional NSBBs such as propanolol.2 Nevertheless, using carvedilol in these non-responders, the benefit would rise to 75% of patients.
FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
Authors: Nicolas Roussot, Julie Lecuelle, Lorraine Dalens, Caroline Truntzer, Francois Ghiringhelli
Journal: Journal for ImmunoTherapy of Cancer (2023)

A novel crosstalk between immunogenic and oncometabolic pathways triggered by T cell-released interferon-gamma (IFN-ɣ) has been recently identified. This IFN-ɣ-pyruvate kinase M2-β-catenin axis relies on fibroblast growth factor 2 (FGF2) signaling in tumor cells and leads to hyperprogressive disease on immune checkpoint blockade (ICB) in preclinical models. This result underlines how IFN-ɣ signaling may have distinct effects on tumor cells depending on their oncogenic and metabolic features. On the basis of these data, this study aims to explore the relationship between genomic tumor FGF2 or FGF/FGF receptor (FGFR) amplification and immunotherapy response in patients with metastatic solid cancers. We used a large genomic data set of 545 ICB-treated patients and compared outcomes between those with and without FGF2 genomic amplification. Patients with no FGF2 genomic amplification had significantly longer progression-free survival (PFS) (HR=0.55 (95% CI 0.4, 0.8); p value=0.005) and overall survival (OS) (HR=0.56 (0.3, 0.9); p value=0.02) than patients harboring an FGF2 amplification. We next questioned whether such an observation may extend to genomic amplification of the FGF/FGFR pathway. Similarly, patients with no FGF/FGFR genomic amplification had longer PFS (HR=0.71 (0.8, 0.9), p value=0.004) and OS (HR=0.77 (0.6, 1); p value=0.06). RNA sequencing analysis of tumors between the amplified and non-amplified populations showed distinct expression profiles concerning oncogenic pathways. Importantly, using a cohort of patients untreated with ICB from the The Cancer Genome Atlas, we show that FGF2 and FGF/FGFR genomic amplification were not associated with prognosis, thus demonstrating that we identified a predictive biomarker of immunotherapy resistance.
Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes
Authors: Tomoya Isobe, Iwo Kucinski, Melania Barile, Xiaonan Wang, Rebecca Hannah, Hugo P. Bastos, Shirom Chabra, M.S. Vijayabaskar, Katherine H.M. Sturgess, Matthew J. Williams, George Giotopoulos, Ludovica Marando, Juan Li, Justyna Rak, Malgorzata Gozdecka, Daniel Prins, Mairi S. Shepherd, Sam Watcham, Anthony R. Green, David G. Kent, George S. Vassiliou, Brian J.P. Huntly, Nicola K. Wilson, Berthold Göttgens
Journal: Cell Genomics (2023)

Acute myeloid leukemia (AML) and myeloid neoplasms develop through acquisition of somatic mutations that confer mutation-specific fitness advantages to hematopoietic stem and progenitor cells. However, our understanding of mutational effects remains limited to the resolution attainable within immunophenotypically and clinically accessible bulk cell populations. To decipher heterogeneous cellular fitness to preleukemic mutational perturbations, we performed single-cell RNA sequencing of eight different mouse models with driver mutations of myeloid malignancies, generating 269,048 single-cell profiles. Our analysis infers mutation-driven perturbations in cell abundance, cellular lineage fate, cellular metabolism, and gene expression at the continuous resolution, pinpointing cell populations with transcriptional alterations associated with differentiation bias. We further develop an 11-gene scoring system (Stem11) on the basis of preleukemic transcriptional signatures that predicts AML patient outcomes. Our results demonstrate that a single-cell-resolution deep characterization of preleukemic biology has the potential to enhance our understanding of AML heterogeneity and inform more effective risk stratification strategies.
Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model
Authors: Jennifer Padilla, Noha M. Osman, Beatrice Bissig-Choisat, Sandra L. Grimm, Xuan Qin, Angela M. Major, Li Yang, Dolores Lopez-Terrada, Cristian Coarfa, Feng Li, Karl-Dimiter Bissig, David D. Moore, Loning Fu
Journal: Journal of Hepatology (2023)
Integration of migrant and refugee data in health information systems in Europe: advancing evidence, policy and practice
Authors: Kayvan Bozorgmehr, Martin McKee, Natasha Azzopardi-Muscat, Jozef Bartovic, Ines Campos-Matos, Tsvetelina-Ivanova Gerganova, Ailish Hannigan, Jelena Janković, Daniela Kállayová, Josiah Kaplan, Ilker Kayi, Elias Kondilis, Lene Lundberg, Isabel de la Mata, Aleksandar Medarević, Jozef Suvada, Kolitha Wickramage, Soorej Jose Puthoopparambil
Journal: The Lancet Regional Health - Europe (2023)

Coverage of migrant and refugee data is incomplete and of insufficient quality in European health information systems. This is not because we lack the knowledge or technology. Rather, it is due to various political factors at local, national and European levels, which hinder the implementation of existing knowledge and guidelines. This reflects the low political priority given to the topic, and also complex governance challenges associated with migration and displacement. We review recent evidence, guidelines, and policies to propose four approaches that will advance science, policy, and practice. First, we call for strategies that ensure that data is collected, analyzed and disseminated systematically. Second, we propose methods to safeguard privacy while combining data from multiple sources. Third, we set out how to enable survey methods that take account of the groups' diversity. Fourth, we emphasize the need to engage migrants and refugees in decisions about their own health data. Based on these approaches, we propose a change management approach that narrows the gap between knowledge and action to create healthcare policies and practices that are truly inclusive of migrants and refugees. We thereby offer an agenda that will better serve public health needs, including those of migrants and refugees and advance equity in European health systems.
Estrogen Replacement and Risk of Alzheimer Disease
Authors: J. Galen Buckwalter, Diana B. Petitti, Valerie C. Crooks
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Estrogen Replacement and Risk of Alzheimer Disease—Reply
Authors: Susan M. Resnick, Victor W. Henderson
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Estrogen Replacement and Risk of Alzheimer Disease
Authors: Lynn Rosenberg
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pharmacist Care for Reactive Airway Disease
Authors: Martin Schulz
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Authors: Michael C. Heinrich, Christopher L. Corless, George D. Demetri, Charles D. Blanke, Margaret von Mehren, Heikki Joensuu, Laura S. McGreevey, Chang-Jie Chen, Annick D. Van den Abbeele, Brian J. Druker, Beate Kiese, Burton Eisenberg, Peter J. Roberts, Samuel Singer, Christopher D.M. Fletcher, Sandra Silberman, Sasa Dimitrijevic, Jonathan A. Fletcher
Journal: Journal of Clinical Oncology (2023)

Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate. The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST.
Flashback Foreword: Kinase Mutations and Imatinib Response in Patients With Metastatic GI Stromal Tumor
Authors: Robert G. Maki
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. October 27, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00213 Journal of Clinical Oncology - published online before print October 27, 2023 PMID: 37890276 Flashback Foreword: Kinase Mutations and Imatinib Response in Patients With Metastatic GI Stromal Tumor Robert G. Maki , MD, PhD, FACP, FASCO1,2,3xRobert G. MakiSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Perelman School of Medicine, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA3Memorial Sloan-Kettering Cancer Center, New York, NY https://doi.org/10.1200/JCO.23.00213 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2003, to our knowledge, Heinrich et al1 demonstrated for the first time in a solid tumor that the specific mutation in a kinase gene (KIT or PDGFRA) in cancer (GI stromal tumor) was associated with quality of the outcome when patients were treated with a kinase inhibitor, imatinib. The biologic principle of the linkage between a driver mutation and response to an oral kinase inhibitor in a solid tumor would become foundational for the treatment of many cancers in the two decades that followed. Companion Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis
Authors: Zhejia Tian, Clara Vollmer Barbosa, Hannah Lang, Johann Bauersachs, Anette Melk, Bernhard M W Schmidt
Journal: Cardiovascular Research (2023)

Resistant hypertension is associated with a high risk of cardiovascular disease, chronic kidney disease, and mortality. Yet, its management is challenging. This study aims to establish the comparative effectiveness of pharmacologic and interventional treatments by conducting a network meta-analysis.
Career advancement for female academic dermatologists: how the pandemic exacerbated inequities, and the path forward
Authors: Ramneek K Dhami, Justin W Ng, Erin L Foster, Emile Latour, Jesse J Keller
Journal: British Journal of Dermatology (2023)

Journal Article Accepted manuscript Career advancement for female academic dermatologists: how the pandemic exacerbated inequities, and the path forward Get access Ramneek K Dhami, Ramneek K Dhami University of Nevada, Reno School of Medicine, Reno, NV, USA https://orcid.org/0000-0003-2409-4067 Search for other works by this author on: Oxford Academic Google Scholar Justin W Ng, Justin W Ng College of Osteopathic Medicine of the Pacific-Northwest, Lebanon, OR, USA Search for other works by this author on: Oxford Academic Google Scholar Erin L Foster, Erin L Foster Department of Dermatology, Oregon Health & Science University, Portland, OR, USA Search for other works by this author on: Oxford Academic Google Scholar Emile Latour, Emile Latour Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA Search for other works by this author on: Oxford Academic Google Scholar Jesse J Keller Jesse J Keller Department of Dermatology, Oregon Health & Science University, Portland, OR, USA Correspondence: Jesse J. Keller, MD, MCR, Email:kellerje@ohsu.edu Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljad422, https://doi.org/10.1093/bjd/ljad422 Published: 27 October 2023 Article history Received: 27 April 2023 Revision received: 20 October 2023 Accepted: 25 October 2023 Published: 27 October 2023
Enzyme‐Triggered Intestine‐Specific Targeting Adhesive Platform for Universal Oral Drug Delivery (Adv. Healthcare Mater. 27/2023)
Authors: Ying Li, Jung Seung Lee, Ameya R. Kirtane, Mengyuan Li, Charles William Coffey, Kaitlyn Hess, Aaron Lopes, Joy Collins, Siddartha Tamang, Keiko Ishida, Alison Hayward, Jacob Wainer, Adam J. Wentworth, Giovanni Traverso
Journal: Advanced Healthcare Materials (2023)

Enzyme-Triggered Adhesives In article 2301033, Giovanni Traverso and co-workers develop an oral sandwiched pill with in situ gelling systems gelled based on enzyme catalyzed crosslinking reactions, which undergo mild conditions, tunable gelation rate, and tough mechanical properties by a simple mixing to deliver clinically-relevant doses of hydrophilic and hydrophobic drugs in a large animal model, with a sustained half life and Tmax compared to conventional pills. This work is seen as a transformative step in drug delivery research that ushers in a new era of oral sustained drug delivery: The invention can not only be used to orally deliver drugs to optimize drugs pharmacokinetics after oral administration, but also can be used in gastrointestinal (GI) diagnoses application to ensure the diagnostic device stays in the GI tract for enough time.